Prediabetic State

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

5100%

+ 10 programs with unclassified modality

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AstraZenecaCAMBRIDGE, United Kingdom

2 programs

Dapagliflozin 10mgPhase 41 trial

DapagliflozinPhase 2Small Molecule1 trial

Active Trials

NCT07624305Not Yet Recruiting2,800Est. Jul 2030

NCT03721874Completed16Est. Jun 2021

Medica CorpMA - Bedford

1 program

Vanadyl sulfatePhase 31 trial

Active Trials

NCT00561132Completed14Est. Nov 2004

SandozAustria - Kundl

1 program

vildagliptinPhase 3Small Molecule

Nordic PharmaFrance - Paris

1 program

DapagliflozinPhase 2Small Molecule

BayerLEVERKUSEN, Germany

1 program

DapagliflozinPhase 2Small Molecule1 trial

Active Trials

NCT02695810Completed120Est. Jan 2019

Colorado TherapeuticsCO - Louisville

2 programs

CookingMattersN/A1 trial

PresessionsN/A1 trial

Active Trials

NCT03527641Completed20Est. Apr 2019

NCT04022499Completed483Est. Aug 2024

LabcorpBURLINGTON, NC

1 program

Development of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetesN/A1 trial

Active Trials

NCT06195566Completed77Est. Sep 2025

Human BioSciencesWV - Martinsburg

1 program

Financial IncentivesN/A1 trial

Active Trials

NCT02422420Completed1,500Est. Sep 2016

Shield TherapeuticsMA - Wellesley

1 program

JOOL Health Mobile Phone ApplicationN/A1 trial

Active Trials

NCT03025607Completed69Est. Mar 2018

Angeles TherapeuticsCA - Los Angeles

1 program

Shared decision-making with pharmacistsN/A1 trial

Active Trials

NCT02384109Completed521Est. Jun 2019

Sharp TherapeuticsPA - Pittsburgh

1 program

Sitagliptin + Pioglitazone PLACEBON/A

MSDIreland - Ballydine

1 program

Sitagliptin + Pioglitazone PLACEBON/A1 trial

Active Trials

NCT01006018Terminated3Est. Dec 2011

NovartisBASEL, Switzerland

1 program

vildagliptinPHASE_3Small Molecule1 trial

Active Trials

NCT00237250Completed171Est. Jul 2006

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

AstraZenecaDapagliflozin 10mg

AstraZenecaDapagliflozin

Novartisvildagliptin

Medica CorpVanadyl sulfate

BayerDapagliflozin

LabcorpDevelopment of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes

Colorado TherapeuticsPresessions

Colorado TherapeuticsCookingMatters

Shield TherapeuticsJOOL Health Mobile Phone Application

Angeles TherapeuticsShared decision-making with pharmacists

Human BioSciencesFinancial Incentives

MSDSitagliptin + Pioglitazone PLACEBO

Clinical Trials (12)

Total enrollment: 5,794 patients across 12 trials

NCT03721874 AstraZenecaDapagliflozin 10mg

Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation

Start: Apr 2019Est. completion: Jun 202116 patients

Phase 4Completed

NCT07624305 AstraZenecaDapagliflozin

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

Start: Sep 2026Est. completion: Jul 20302,800 patients

Phase 3Not Yet Recruiting

NCT00237250 Novartisvildagliptin

Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

Start: Oct 2005Est. completion: Jul 2006171 patients

Phase 3Completed

NCT00561132 Medica CorpVanadyl sulfate

Study of Vanadium Supplement in Patients With Impaired Glucose Tolerance

Start: Nov 2003Est. completion: Nov 200414 patients

Phase 3Completed

NCT02695810 BayerDapagliflozin

The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes

Start: Feb 2016Est. completion: Jan 2019120 patients

Phase 2Completed

NCT06195566 LabcorpDevelopment of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes

Development of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes

Start: Jan 2024Est. completion: Sep 202577 patients

N/ACompleted

NCT04022499 Colorado TherapeuticsPresessions

Presessions for the National Diabetes Prevention Program

Start: Aug 2019Est. completion: Aug 2024483 patients

N/ACompleted

NCT03527641 Colorado TherapeuticsCookingMatters

United for Health: Type 2 Diabetes Prevention in Latino Teens

Start: May 2018Est. completion: Apr 201920 patients

N/ACompleted

NCT03025607 Shield TherapeuticsJOOL Health Mobile Phone Application

A Mobile Phone-based Program for Adults With Prediabetes

Start: May 2017Est. completion: Mar 201869 patients

N/ACompleted

NCT02384109 Angeles TherapeuticsShared decision-making with pharmacists

A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program

Start: Jun 2015Est. completion: Jun 2019521 patients

N/ACompleted

NCT02422420 Human BioSciencesFinancial Incentives

Minnesota Medicaid Incentives to Prevent Chronic Disease

Start: Mar 2013Est. completion: Sep 20161,500 patients

N/ACompleted

NCT01006018 MSDSitagliptin + Pioglitazone PLACEBO

DPP-4 Inhibition and TZD for DM Prevention

Start: Jul 2011Est. completion: Dec 20113 patients

N/ATerminated

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.